Physician profile
Keith D Nord
NPI 1033180948
$286,449.33
in general payments reported to CMS, 2019-2025
33 companies · $3,528 in 2025
The $3,528 reported for 2025 was more than what 79% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $77K · 2020: $61K · 2021: $77K · 2022: $64K · 2023: $1,978 · 2024: $1,458 · 2025: $3,528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,753 · Food and Beverage: $2,519 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,752.80 |
| Food and Beverage | $2,518.52 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,692.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $277,470.97 | 2019-2023 | |
| Dunamis Medical, LLC | $2,816.43 | 2020-2025 | |
| Gentleman Orthopedic Solutions | $2,312.71 | 2019-2023 | |
| Sonex Health, INC. | $1,285.32 | 2024-2025 | Sx-One Microknife |
| Axogen | $474.72 | 2022-2025 | Avance Nerve Graft |
| Smith+Nephew, INC. | $220.97 | 2021-2024 | Bioinductive Implant With Arthroscopic Delivery System - Medium, Na |
| Depuy Synthes Sales INC. | $194.96 | 2019-2023 | Monovisc, Orthovisc |
| Acumed LLC | $189.45 | 2023 | Acumed |
| Stryker Corporation | $176.39 | 2021 | |
| Endo Pharmaceuticals INC. | $176.11 | 2019-2024 | Xiaflex |
| Pacira Pharmaceuticals Incorporated | $137.77 | 2022-2025 | Zilretta, Iovera, Exparel |
| Ferring Pharmaceuticals INC. | $126.41 | 2021-2025 | Euflexxa |
| Pacira Therapeutics, INC. | $114.35 | 2019-2021 | |
| Endo USA, INC. | $85.49 | 2024-2025 | Xiaflex |
| Checkpoint Surgical, INC | $76.72 | 2023 | Checkpoint Stimulators |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Djo, LLC | $69.92 | 2023-2025 | Cmf |
| Kowa Pharmaceuticals America, INC. | $61.85 | 2022 | |
| Pfizer INC. | $61.65 | 2020-2021 | |
| Avanos Medical | $51.82 | 2019-2022 | |
| Linvatec Corporation | $49.64 | 2025 | Biobrace 23mm |
| Vertex Pharmaceuticals Incorporated | $48.55 | 2025 | |
| Merck Sharp & Dohme LLC | $39.92 | 2024-2025 | Bridion |
| Bioventus LLC | $34.79 | 2019-2022 | |
| Molnlycke Health Care US, LLC | $30.16 | 2022 | |
| Heron Therapeutics, INC. | $27.05 | 2024 | Zynrelef |
| Fidia Pharma USA INC. | $19.30 | 2024 | Hyalgan, Hymovis, Triluron |
| Orthofix Medical, INC. | $16.70 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $16.04 | 2020 | |
| Kinex Medical Company LLC | $15.41 | 2021 | |
| Orthogenrx INC. | $13.43 | 2021 | |
| Amgen INC. | $12.65 | 2022 | |
| Sanofi-Aventis U.S. LLC | $11.80 | 2019 | |
| Heraeus Medical, LLC. | $9.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,844.39 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Nord listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.